1207965-12-5

Basic information

• Product Name: N-(2-amino-2-oxoethyl)-3-{2-[3-(trifluoromethyl)benzyl]-1-benzothiophen-7-yl}benzamide
• Synonyms: N-(2-amino-2-oxoethyl)-3-{2-[3-(trifluoromethyl)benzyl]-1-benzothiophen-7-yl}benzamide
• CAS NO: 1207965-12-5
• Molecular Weight: 468.499
• Mol File: 1207965-12-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-(2-amino-2-oxoethyl)-3-{2-[3-(trifluoromethyl)benzyl]-1-benzothiophen-7-yl}benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-amino-2-oxoethyl)-3-{2-[3-(trifluoromethyl)benzyl]-1-benzothiophen-7-yl}benzamide(1207965-12-5)
• EPA Substance Registry System: N-(2-amino-2-oxoethyl)-3-{2-[3-(trifluoromethyl)benzyl]-1-benzothiophen-7-yl}benzamide(1207965-12-5)

Safety Data

• Hazardous Substances Data: 1207965-12-5(Hazardous Substances Data)

Upstream product

• 19075-59-3 7-bromo-1-benzothiophene-2-carboxylic acid 
• 1207970-84-0 ethyl 3-{2-[3-(trifluoromethyl)benzyl]-1-benzothiophen-7-yl}benzoate 
• 1613391-10-8 C₂₃H₁₅F₃O₂S 
• 598-41-4 H-Gly-NH₂ 
• 1423-26-3 (meta-(trifluoromethyl)phenyl)boronic acid 
• 1207970-63-5 ethyl 3-[2-(bromomethyl)-1-benzothiophen-7-yl]benzoate 
• 1207970-52-2 ethyl 3-[2-(Hydroxymethyl)-1-benzothiophen-7-yl]benzoate 
• 1171926-64-9 (7-bromo-1-benzothiophen-2-yl)methanol 
• 1668-10-6 glycinamide hydrochloride 

Relevant articles and documents

Discovery of the first potent and orally available agonist of the orphan G-protein-coupled receptor 52

G-protein-coupled receptor 52 (GPR52) is an orphan Gs-coupled G-protein-coupled receptor. GPR52 inhibits dopamine D2 receptor signaling and activates dopamine D1/N-methyl-d-aspartate receptors via intracellular cAMP accumulation, and therefore, GPR52 agonists may have potential as a novel class of antipsychotics. A series of GPR52 agonists with a bicyclic core was designed to fix the conformation of the phenethyl ether moiety of compounds 2a and 2b. 3-[2-(3-Chloro-5-fluorobenzyl)-1-benzothiophen-7-yl]-N- (2-methoxyethyl)benzamide 7m showed potent activity (pEC50 = 7.53 ± 0.08) and good pharmacokinetic properties. Compound 7m significantly suppressed methamphetamine-induced hyperactivity in mice after oral administration of 3 mg/kg without disturbance of motor function.